Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy

Epilepsy Research

Volumn 94, Issue 3, 2011, Pages 206-212

  Liimatainen, Suvi ^a   Lehtimäki, Kai ^a   Raitala, Annika ^b   Peltola, Maria ^a   Oja, Simo S ^a   Peltola, Jukka ^a   Hurme, Mikko A ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Cytokine; Idiopathic epilepsy; Primary generalized epilepsy; Temporal lobe epilepsy

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FREQUENCY ANALYSIS; GENERALIZED EPILEPSY; HIPPOCAMPAL SCLEROSIS; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MYOCLONUS EPILEPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; TEMPORAL LOBE EPILEPSY;

ADULT; EPILEPSY, GENERALIZED; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; SEROTONIN; TRYPTOPHAN;

EID: 79955522228     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.02.003     Document Type: Article

References (44)

1. Ahmad S., Fowler L.J., Whitton P.S. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. 2005, 63:141-149.
2. Balosso S., Ravizza T., Perego C., Peschon J., Campbell I.L., De Simoni M.G., Vezzani A. Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann. Neurol. 2005, 57:804-812.
3. Bercovici E., Cortez M.A., Snead O.C. 5-HT2 modulation of AY-9944 induced atypical absence seizures. Neurosci. Lett. 2007, 418:13-17.
4. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA 1993, 90:10061-10065.
5. Chiarugi A., Meli E., Moroni F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 2001, 77:1310-1318.
6. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989, 30:389-399.
7. Commission on Neuroimaging of the International League Against Epilepsy Recommendations for neuroimaging of patients with epilepsy. Epilepsia 1997, 38:1255-1256.
8. De Ponti F., Lecchini S., Cosentino M., Castelletti C.M., Malesci A., Frigo G.M. Immunological adverse effects of anticonvulsants. What is their clinical relevance?. Drug Safety 1993, 8:235-250.
9. Dufour-Rainfray D., Vourc'h P., Le Guisquet A.M., Garreau L., Ternant D., Bodard S., Jaumain E., Gulhan Z., Belzung C., Andres C.R., Chalon S., Guilloteau D. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci. Lett. 2010, 470:55-59.
10. Graf M., Jakus R., Kantor S., Levay G., Bagdy G. Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci. Lett. 2004, 359:45-48.
11. Hasler G., Bonwetsch R., Giovacchini G., Toczek M.T., Bagic A., Luckenbaugh D.A., Drevets W.C., Theodore W.H. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol. Psychiatry 1997, 62:1258-1264.
12. Hesdorffer D.C., Hauser W.A., Olafsson E., Ludvigsson P., Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann. Neurol. 2006, 59:35-41.
13. Kälviäinen R., Salmenperä T., Partanen K., Vainio P., Riekkinen P., Pitkänen A. Recurrent seizures may cause hippocampal damage in temporal lobe epilepsy. Neurology 1998, 50:1377-1382.
14. Kanemoto K., Kawasaki J., Miyamoto T., Obayashi H., Nishimura M. Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Ann. Neurol. 2000, 47:571-574.
15. Kanner A.M., Balabanov A. Depression and epilepsy: how closely related are they?. Neurology 2002, 58:S27-39.
16. Kwidzinski E., Bunse J., Aktas O., Richter D., Mutlu L., Zipp F., Nitsch R., Bechmann I. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 2005, 19:1347-1349.
17. Kwidzinski E., Bunse J., Kovac A.D., Ullrich O., Zipp F., Nitsch R., Bechmann I. IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. Adv. Exp. Med. Biol. 2003, 527:113-118.
18. Laich A., Neurauter G., Widner B., Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin. Chem. 2002, 48:579-581.
19. Lehtimäki K., Keränen T., Huhtala H., Hurme M., Ollikainen J., Honkaniemi J., Palmio J., Peltola J. Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration. J. Neuroimmunol. 2004, 152:121-125.
20. Lehtimäki K.A., Keränen T., Palmio J., Mäkinen R., Hurme M., Honkaniemi J., Peltola J. Increased plasma levels of cytokines after seizures in localization-related epilepsy. Acta Neurol. Scand. 2007, 116:226-230.
21. Liimatainen S., Fallah M., Kharazmi E., Peltola M., Peltola J. Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy. J. Neurol. 2009, 256:796-802.
22. Liimatainen S., Peltola M., Fallah M., Kharazmi E., Haapala A.M., Peltola J. The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. Eur. J. Neurol. 2009, 16:134-141.
23. Liimatainen S., Peltola M., Sabater L., Fallah M., Kharazmi E., Haapala A.M., Dastidar P., Knip M., Saiz A., Peltola J. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010, 51:760-767.
24. Majoie H.J., de Baets M., Renier W., Lang B., Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res. 2006, 71:135-141.
25. Majoie H.J., Rijkers K., Berfelo M.W., Hulsman J.A., Myint A., Schwarz M., Vles J.S. Vagus nerve stimulation in refractory epilepsy: effects on pro- and anti-inflammatory cytokines in peripheral blood. Neuroimmunomodulation 2011, 18:52-56.
26. Mellor A.L., Munn D.H. Ido expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4:762-774.
27. Meschaks A., Lindstrom P., Halldin C., Farde L., Savic I. Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. Arch. Neurol. 2005, 62:946-950.
28. Miura H., Ozaki N., Sawada M., Isobe K., Ohta T., Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008, 11:198-209.
29. Monckton J.E., McCormick D.A. Neuromodulatory role of serotonin in the ferret thalamus. J. Neurophysiol. 2002, 87:2124-2136.
30. Müller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
31. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 2003, 61:519-525.
32. Peltola J., Hurme M., Miettinen A., Keränen T. Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res. 1998, 31:129-133.
33. Peltola J.T., Haapala A., Isojärvi J.I., Auvinen A., Palmio J., Latvala K., Kulmala P., Laine S., Vaarala O., Keränen T. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am. J. Med. 2000, 15:712-717.
34. Peltola J., Palmio J., Korhonen L., Suhonen J., Miettinen A., Hurme M., Lindholm D., Keränen T. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res. 2000, 41:205-211.
35. Peltola M., Kaukinen K., Dastidar P., Haimila K., Partanen J., Haapala A.M., Mäki M., Keränen T., Peltola J. Hippocampal sclerosis in refractory temporal lobe epilepsy is associated with gluten sensitivity. J. Neurol. Neurosurg. Psychiatry 2009, 80:626-630.
36. Ravizza T., Boer K., Redeker S., Spliet W.G., van Rijen P.C., Troost D., Vezzani A., Aronica E. The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol. Dis. 2006, 24:128-143.
37. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
38. Shehata G.A., Bateh Ael-A Cognitive function, mood, behavioral aspects, and personality traits of adult males with idiopathic epilepsy. Epilepsy Behav. 2009, 14:121-124.
39. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am. J. Psychiatry 2003, 160:1516-1518.
40. Sheng J.G., Boop F.A., Mrak R.E., Griffin W.S. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J. Neurochem. 1994, 63:1872-1879.
41. Sporer K.A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Safety 1995, 13:94-104.
42. Tellez-Zenteno J.F., Patten S.B., Jetté N., Williams W., Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-2344.
43. Vezzani A., Conti M., De Luigi A., Ravizza T., Moneta D., Marchesi F., De Simoni M.G. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J. Neurosci. 1999, 19:5054-5065.
44. Vezzani A., Moneta D., Richichi C., Aliprandi M., Burrows S.J., Ravizza T., Perego C., De Simoni M.G. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002, 43(Suppl. l5):30-35.